Small intestinal bacterial overgrowth is one of the few conditions where the published guidelines and the clinical reality diverge sharply. The evidence base is built almost entirely around hydrogen-predominant disease, yet many of the clients I see produce all three fermentation gases at once. This review pairs what the trials actually show with the root-cause thinking that the guidelines leave out.

SIBO is increasingly diagnosed across a range of gastrointestinal and non-gastrointestinal presentations, but its definition remains contested and its true prevalence undefined.¹ When a breath test returns elevated hydrogen and methane and a clinical picture suggestive of hydrogen sulfide, the clinician is working past the edge of the published map. There are no guidelines and no high-quality trials that address triple-gas SIBO directly. A defensible strategy has to be assembled from the evidence for each gas-producing phenotype, layered onto a functional-medicine assessment of why the overgrowth happened in the first place.

One label, three different ecosystems

The single most useful conceptual shift in SIBO is recognizing that each breath-test gas reflects a distinct microbial population with distinct drug susceptibilities. “Treating SIBO” without specifying the gas is like prescribing an antibiotic without naming the organism.

Table 1. Gas phenotype, dominant organism, and the implication for therapy.

Because elevated methane suppresses hydrogen on the breath test, and because H₂S has historically been invisible to two-gas devices, a “mixed” picture is almost certainly under-recognized rather than rare.¹

The evidence-based foundation

Both major North American statements — the American Gastroenterological Association (AGA) Clinical Practice Update and the American College of Gastroenterology (ACG) guideline — agree that antibiotic therapy for SIBO remains empiric, broad in coverage, and brief.^1,2 The AGA is explicit that the database guiding antibiotic strategy is limited, that the goal is not to sterilize the small bowel but to modulate its flora toward symptom relief, and that a single 7- to 10-day course improves symptoms in roughly 46–90% of individuals and normalizes the breath test in 20–75%.¹

Hydrogen-dominant disease  ●●● STRONG

Rifaximin is the most-studied agent. A systematic review and meta-analysis of 32 studies (1,331 participants) found an overall eradication rate of 70.8% by intention-to-treat.³ Meta-regression identified drug dose, study design, and co-therapy as independent predictors of success — clinically meaningful because dose-finding work shows 1,200 mg/day outperforms 600–800 mg/day over 7 days.³ When rifaximin is unavailable or cost-prohibitive (it is not an FDA-approved indication for SIBO in the United States), the guidelines describe systemic alternatives such as ciprofloxacin, metronidazole, amoxicillin-clavulanate, or tetracycline for 7–14 days.¹

Methane-dominant disease (intestinal methanogen overgrowth)  ●●○ MODERATE

Methanogens are archaea, not bacteria, and are inherently resistant to many standard antibiotics — which is precisely why rifaximin monotherapy underperforms here. In a study of methane-positive individuals, the combination of rifaximin (400 mg three times daily) plus neomycin (500 mg twice daily) eradicated methane in 87%, versus 28% with rifaximin alone and 33% with neomycin alone.⁴ The AGA appropriately frames this as a single uncontrolled (retrospective) trial, but it remains the most evidence-supported regimen for the methane component.^1,4

Hydrogen sulfide disease  ●○○ EMERGING

This is the least-characterized phenotype, and there are no clinical trials targeting H₂S-SIBO with antibiotics. The most relevant intervention comes from outside the antibiotic literature entirely: bismuth subsalicylate binds sulfide directly. In a human study, oral bismuth subsalicylate (524 mg four times daily) produced a greater-than-95% reduction in fecal H₂S release.⁵ That study was conducted in healthy volunteers and fecal homogenates rather than in a SIBO cohort, so it speaks to mechanism and sulfide reduction rather than to eradication — an important distinction to keep in front of clients. Rifaximin’s broad spectrum may have some activity against sulfate-reducing bacteria, but this has never been studied specifically in H₂S disease.

Where functional medicine adds value

Evidence-based protocols tell us how to kill the bugs. They say very little about why a particular client grew them, or how to keep them from returning. This is where a functional-medicine lens earns its place — not as an alternative to the trials, but as the scaffolding around them.

1. Treat the terrain, not just the gas  ●●● STRONG  (as a principle)

The AGA’s own best-practice advice states that management should focus on identifying and correcting underlying causes, not merely administering antibiotics.¹ The most common reasons SIBO recurs are mechanical and physiologic: impaired motility and a weak migrating motor complex (the “housekeeper wave”), post-infectious autoimmunity targeting vinculin after a bout of food poisoning, structural issues (adhesions, diverticula, a lax ileocecal valve), hypochlorhydria — frequently iatrogenic from chronic proton-pump inhibitor use — and bile-acid or pancreatic-enzyme insufficiency. A functional work-up asks which of these applies to this client before, during, and after antimicrobial therapy.

2. Herbal antimicrobials — surprisingly evidence-supported  ●●○ MODERATE

This is the bridge most clients are surprised to learn exists. In a comparative study from a tertiary referral center, herbal antimicrobial therapy normalized the lactulose breath test in 46% of individuals, statistically comparable to the 34% achieved by rifaximin (P = .24).⁶ Just as importantly, among those who had already failed rifaximin, herbal rescue therapy normalized the breath test in 57% — essentially equivalent to the 60% achieved by triple antibiotics — and the herbal arm reported markedly fewer adverse effects.⁶ The study was retrospective and the regimens were not perfectly standardized, so this is supportive rather than definitive, but it is real comparative data, not folklore. Common evidence-aligned botanicals include berberine-containing compounds, oregano oil, and allicin (the last being a rational first choice for the methane component, given its activity against methanogens).

Berberine is now being tested head-to-head: the registered BRIEF-SIBO trial is a non-inferiority study comparing two weeks of berberine against rifaximin, using the meta-analytic 72.9% per-protocol eradication rate as its benchmark.⁷ Results will help move botanicals from “moderate” toward “strong” — or not.

3. Biofilm and substrate strategy  ●○○ EMERGING

Two adjuncts have mechanistic rationale and growing clinical use, though limited randomized support. Biofilm-disrupting agents (such as N-acetylcysteine) are used to improve antimicrobial access to organisms that shelter in matrix. And substrate restriction — a low-FODMAP or low-fermentation approach, with a specific low-sulfur emphasis when H₂S is in play — reduces the fuel available to gas-producing organisms. Diet is a lever for symptom control and recurrence reduction rather than a stand-alone eradication tool, and prolonged restriction risks nutritional and microbiome harm, so it should be time-limited.

4. Prokinetics — including a role for LDN  ●○○ EMERGING

If a weak migrating motor complex let the overgrowth develop, restoring motility after the kill phase is the single highest-yield recurrence-prevention move. Conventional options include low-dose nocturnal erythromycin (a motilin agonist) and prucalopride.¹ Herbal prokinetics such as ginger and the botanical preparation STW-5 (Iberogast) are gentler alternatives.

Low-dose naltrexone (LDN) deserves specific mention in this context. Beyond its endorphin-mediated, anti-inflammatory effects, opioid-antagonist signaling influences the migrating motor complex, and clinicians experienced with SIBO use LDN as an adjunctive prokinetic — particularly in clients with overlapping autoimmune, dysautonomic, or mast-cell features. The supporting data are mechanistic and observational (animal models plus limited human experience), and randomized trials in SIBO are not yet available, so this remains an emerging, individualized strategy rather than a guideline recommendation.

5. Repair and restore  ●○○ EMERGING

Maldigestion and malabsorption are part of the SIBO syndrome,¹ so correcting deficiencies — fat-soluble vitamins, B12, iron — and supporting the gut-brain axis (vagal tone, sleep, stress physiology) belong in any durable plan. These measures rarely eradicate overgrowth on their own, but they address the downstream cost of having had it.

A pragmatic, sequenced protocol for mixed-gas SIBO

There are no randomized trials evaluating combination strategies targeting all three gases simultaneously; what follows is a reasonable empiric framework assembled from the single-gas evidence above and tailored at the individual level.

The recurrence problem

Recurrence is not the exception in SIBO — it is closer to the rule. In a landmark cohort, glucose-breath-test positivity returned in 12.6% of individuals at 3 months, 27.5% at 6 months, and 43.7% at 9 months after successful decontamination.⁸ The strongest predictors were older age, a history of appendectomy, and chronic PPI use,^1,8 which maps almost perfectly onto the functional-medicine “terrain” argument: the people who relapse are usually those whose underlying motility, anatomy, or acid physiology was never addressed. Mitigation rests on prokinetics, occasional cyclical or rotating antimicrobial courses, and dietary modification — and, above all, on having corrected the root cause during the first round rather than simply re-treating the gas.

The honest bottom line: the evidence base for treating mixed-gas SIBO is extrapolated from single-phenotype studies, and no randomized trial has yet tested all three gases together. That uncertainty is not a reason to abandon evidence — it is a reason to combine the best available trial data with disciplined root-cause reasoning, and to grade every recommendation honestly so clients understand what is proven and what is reasoned.

References

1. Quigley EMM, Murray JA, Pimentel M. AGA Clinical Practice Update on Small Intestinal Bacterial Overgrowth: Expert Review. Gastroenterology. 2020;159(4):1526–1532. doi:10.1053/j.gastro.2020.06.090
2. Pimentel M, Saad RJ, Long MD, Rao SSC. ACG Clinical Guideline: Small Intestinal Bacterial Overgrowth. Am J Gastroenterol. 2020;115(2):165–178. doi:10.14309/ajg.0000000000000501
3. Gatta L, Scarpignato C. Systematic review with meta-analysis: rifaximin is effective and safe for the treatment of small intestine bacterial overgrowth. Aliment Pharmacol Ther. 2017;45(5):604–616. doi:10.1111/apt.13928
4. Low K, Hwang L, Hua J, Zhu A, Morales W, Pimentel M. A combination of rifaximin and neomycin is most effective in treating irritable bowel syndrome patients with methane on lactulose breath test. J Clin Gastroenterol. 2010;44(8):547–550. doi:10.1097/MCG.0b013e3181c64c90
5. Suarez FL, Furne JK, Springfield J, Levitt MD. Bismuth subsalicylate markedly decreases hydrogen sulfide release in the human colon. Gastroenterology. 1998;114(5):923–929. doi:10.1016/s0016-5085(98)70311-7
6. Chedid V, Dhalla S, Clarke JO, et al. Herbal therapy is equivalent to rifaximin for the treatment of small intestinal bacterial overgrowth. Glob Adv Health Med. 2014;3(3):16–24. doi:10.7453/gahmj.2014.019
7. Berberine and rifaximin effects on small intestinal bacterial overgrowth (BRIEF-SIBO): study protocol for a double-arm, open-label, randomized clinical trial. Front Pharmacol. 2023;14:1121435. doi:10.3389/fphar.2023.1121435
8. Lauritano EC, Gabrielli M, Scarpellini E, et al. Small intestinal bacterial overgrowth recurrence after antibiotic therapy. Am J Gastroenterol. 2008;103(8):2031–2035. doi:10.1111/j.1572-0241.2008.02030.x

All citations were verified against primary sources prior to publication.

Clinical care is provided through Direct Integrative Care (www.directintegrativecare.com).